Monday, October 10, 2022 2:21:07 PM
Rick
Good article. Agrees with my research the past couple of years. Some of my background is forensic engineering and I definitely get into the weeds for many of my clients. Bioengineering issues are fairly easy to assess.
Good article. Agrees with my research the past couple of years. Some of my background is forensic engineering and I definitely get into the weeds for many of my clients. Bioengineering issues are fairly easy to assess.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
